Inclusion Criteria:  Under care of physician at least 2 months for CKD Not on active Vitamin D and Calcimimetic therapy for at least 4 weeks prior If taking phosphate binders, on a stable regimen at least 4 weeks prior  For entry into Pretreatment Phase:  iPTH at least 120 pg/mL GFR of 15-60 mL/min and no dialysis expected for at least 6 months  For entry into Treatment Phase:  Average of 2 consecutive iPTH values of at least 150 pg/mL, taken at least 1 day apart (all values not less than 120 pg/mL) 2 consecutive corrected serum calcium levels between 8.0-10.0 mg/dL 2 consecutive serum phosphorus levels of not more than 5.2 mg/mL  Exclusion Criteria:  Subjects who had Primary hyperparathyroidism; Subjects with a history of acute renal failure; Subjects with chronic gastrointestinal disease or severe liver disease with clinical symptoms; Subjects with a history of unstable angina, grade III or IV congestive heart failure, and/or clinically meaningful arrhythmia; Subjects with serum albumin < 30g/L, serum hemaoglobin < 85g/L, or serum transaminase higher than 2.5 times the upper limit of nomal; Subjects with a history of malignancy; Subjects who plan to undergo surgery during the study period; Subjects with a history active granulomatous diseases; Subject with a history of alcohol abuse and drug abuse; Human immunodeficiency virus antibody (HIV-Ab), hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab) or Treponema pallidum antibody (TP-Ab) are positive; Subjects who are allergic to the test drug and its ingredients or excipients; Subjects who combined with systemic or systemic diseases that are not suitable for clinical trials; Subjects who have participated in clinical trials of other drugs or devices;